Short Interest in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Drops By 9.3%

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 220,400 shares, a decrease of 9.3% from the March 15th total of 242,900 shares. Based on an average daily volume of 70,600 shares, the short-interest ratio is currently 3.1 days. Approximately 1.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On Eton Pharmaceuticals

Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at about $46,000. Virtu Financial LLC acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $57,000. Renaissance Technologies LLC bought a new position in shares of Eton Pharmaceuticals during the 1st quarter worth approximately $52,000. Jane Street Group LLC bought a new stake in Eton Pharmaceuticals in the 4th quarter valued at $43,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Eton Pharmaceuticals during the 1st quarter valued at $77,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Price Performance

Shares of ETON stock traded down $0.05 during trading hours on Wednesday, hitting $3.14. 94,860 shares of the company’s stock were exchanged, compared to its average volume of 69,317. Eton Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $5.81. The stock’s 50-day moving average is $4.06 and its 200-day moving average is $4.13.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.05). Eton Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 6.21%. The firm had revenue of $7.31 million for the quarter, compared to analyst estimates of $7.70 million. Equities research analysts expect that Eton Pharmaceuticals will post 0.26 EPS for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.